Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 6;114(10):1313-1314.
doi: 10.1093/jnci/djac129.

Encouraging Rigorous Patient-Generated Data All Along the Drug Development Continuum

Vishal Bhatnagar  1 , Paul G Kluetz  1
Affiliations
Editorial

Encouraging Rigorous Patient-Generated Data All Along the Drug Development Continuum

Vishal Bhatnagar et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment in

  • Listening to the Patient Voice Adds Value to Cancer Clinical Trials.
    Brundage MD, Crossnohere NL, O'Donnell J, Cruz Rivera S, Wilson R, Wu AW, Moher D, Kyte D, Reeve BB, Gilbert A, Chen RC, Calvert MJ, Snyder C. Brundage MD, et al. J Natl Cancer Inst. 2022 Oct 6;114(10):1323-1332. doi: 10.1093/jnci/djac128. J Natl Cancer Inst. 2022. PMID: 35900186 Free PMC article.

Comment on

  • Listening to the Patient Voice Adds Value to Cancer Clinical Trials.
    Brundage MD, Crossnohere NL, O'Donnell J, Cruz Rivera S, Wilson R, Wu AW, Moher D, Kyte D, Reeve BB, Gilbert A, Chen RC, Calvert MJ, Snyder C. Brundage MD, et al. J Natl Cancer Inst. 2022 Oct 6;114(10):1323-1332. doi: 10.1093/jnci/djac128. J Natl Cancer Inst. 2022. PMID: 35900186 Free PMC article.

References

    1. Brundage M, Crossnohere N, O’Donnell J, et al. Listening to the patient voice adds value to cancer clinical trials. J Natl Cancer Inst. 2022;114(10);1323-1332. - PMC - PubMed
    1. Lemery S, Pazdur R. Approvals in 2021: dangling accelerated approvals, drug dosing, new approvals and beyond. Nat Rev Clin Oncol. 2022;19(4):217-218. doi:10.1038/s41571-022-00605-5 - DOI - PMC - PubMed
    1. Shah M, Rahman A, Theoret M, et al. The drug-dosing conundrum in oncology—when less is more? N Engl J Med. 2021;385(16):1445-1447. doi:10.1056/NEJMp2109826 - DOI - PubMed
    1. Arora S, Narayan P, Ison G, et al. U.S. FDA drug approvals for gynecological malignancies: a decade in review. Clin Cancer Res. 2022;28(6):1058-1071. doi:10.1158/1078-0432.CCR-21-2599 - DOI - PMC - PubMed
    1. Beaver J, Pazdur R. The wild west of checkpoint inhibitor development. N Engl J Med. 2022;386(14):1297-1301. doi:10.1056/NEJMp2116863 - DOI - PubMed